Constitutively active intracellular signaling drives and sustains cancer growth.
Introduction
The mTOR signaling pathway is an important regulator of cellular homeostasis. By integrating inputs pertaining to nutrient, growth factor and energy levels, its output determines if a cell engages in anabolic processes (protein, nucleotide or lipid synthesis) under favourable conditions, or catabolic processes such as autophagy under adverse conditions [1] . mTOR is a serine/threonine kinase that forms two distinct multi-protein complexes: the raptor containing mTOR complex 1 (mTORC1) and rictor containing mTORC2. mTORC1 is regulated by nutrient availability and broadly controls translation, autophagy and metabolic processes. mTORC2 meanwhile, is growth factor regulated and via an important substrate, the Akt oncogene, controls cell survival.
Due to its critical role at the intersection between cell growth, metabolism and proliferation, dysregulated mTOR signaling is a frequent event in cancer [2] . Mutation of mTOR regulators such as TSC1/TSC2 or PTEN (that negatively regulate mTORC1 and mTORC2 respectively) are common oncogenic events that result in constitutive mTOR activity. Constant mTOR signaling provides support for cellular hyper-proliferation from the increased synthesis of required proteins and cellular building blocks.
We previously described an mTORC2 addicted cell model where murine mast cells are transformed by constitutive mTORC2 signaling following mutagenic knock-out of PTEN [3] . As a consequence these cells are exquisitely sensitive to mTOR inhibition compared to the parent cell line. A genome-wide shRNA screen identified genes that are conditionally essential for growth and survival only under an mTORC2-driven oncogenic program. These hits are thus candidate genes for effector proteins that are responsible for executing essential functions upon mTORC2 hyperactivation.
To confirm these hits, we re-screened the top 25 hits in an isogenic cell panel. Two independent PTEN deficient lines were derived from the parental cell line. In addition, the bcr-abl oncoprotein was used to transform the parental cell line via an alternative oncogenic pathway. The screen confirmed that these genes were also essential in the newly generated PTEN-/mTORC2-addicted cell models. Strikingly none of the genes were essential in the bcr-abl transformed line.
Here, we extended the study to a panel of human cancer cell lines.
Two PTEN negative cell lines with high basal mTORC2 activity (OPM2, Jurkat) were selected, a PTEN positive leukemia cell line HL60, and a bcr-abl transformed CML cell line (K562). shRNA screening of the human counterparts of the hits previously validated in the murine cell line panel revealed that a substantial fraction were also essential for survival in the human cell line panel, with the exception of K562 where shRNA knockdown of these genes had little to no impact on growth and survival. Pharmacological inhibition of mTOR also had the least effect on K562 compared to the other cell lines, indicating that mTOR is not as critically required in bcr-abl mediated transformation. These results show that bcr-abl mediated transformation is distinct from oncogenic programs where mTOR is constitutively activated (as in the case of PTEN loss), or has been recruited to support cancer cell growth.
Results

In vitro transformation of mast cells
We previously described an in vitro transformation system based on murine PB3c mast cells [4] . Parental 15V4 cells are dependent on exogenous interleukin-3 (IL3) for in vitro growth and survival. These cells can be transformed to acquire growth factor independence, a hallmark of cancer, by various routes [3] [4] [5] . Transformation to IL3 independence can be achieved by loss of Pten expression via mutagenesis (6.5 and 6.8 cells), and is phenocopied by stable shRNA knockdown of Pten (shP) ( Fig 1A) . The Ptencell lines have hyperactive mTORC2 signaling as measured by phosphorylation of Akt at serine 473 ( Fig 1B) . Although mTORC1 activity is also increased in the Pten deficient cell lines (at threonine 389 of the mTORC1 target S6K), we previously showed that these cells are addicted to mTORC2 and not mTORC1 signaling for growth and survival [3] . An alternative route of in vitro transformation in this system is expression of the bcr-abl oncoprotein in 15V4 cells to generate IL3 independent b-abl cells ( Fig   1A) [6] . Unlike the Pten deficient cell lines, b-abl cells have similar basal levels of mTORC2 activity as the parental cells and a slight increase in mTORC1 signaling ( Fig 1B) .
In these cells, IL3 signaling remains intact despite having lost their requirement for IL3. 6.8 cells are sensitive to rapamycin, as anticipated due to its addiction to mTORC2 signaling ( Fig 1C) . However rapamycin sensitivity is rescued by exogenous IL3, indicating that loss of mTORC2 signaling can be compensated by stimulation of IL3 signaling. Similar results were obtained with 6.5 and shP (data not shown). b-abl cells however, are sensitive to the bcr-abl inhibitor Glivec in the absence of IL3 and are rescued by exogenous IL3.
In these titrations, b-abl cells are rapamycin insensitive while the 6.8 cells are Glivec insensitive arguing that different downstream signaling pathways are activated to confer IL3 independence. Nonetheless both loss of mTOR or bcr-abl signaling can be compensated by IL3 signaling.
Genes essential in mTORC2 addicted cells are not required in bcr-abl transformed cells
The ability to rescue cell lethality with exogenous IL3 allows identification of genes whose knockdown is conditionally lethal only in the absence of IL3.
This was previously exploited to identify genes required for mTORC2 driven IL3 independent growth in 6.5, 6.8 and shP by a genome-wide shRNA screen [3] . To see if any of these genes are shared in common in bcr-abl mediated IL3 independence, we selected 25 of the highest scoring genes for screening in b-abl (the screen was repeated for 6.5, 6.8 and shP). For each gene, cells were infected with a lentivirus bearing the respective targeting shRNA (typically 5 different shRNA contructs per gene) in the presence or absence of IL3, and growth measured 5 days post-infection. Thus for each shRNA construct, a ratio of inhibition (RI) could be calculated by dividing proliferation +IL3 /proliferation -IL3 (normalized to infection by a nontargeting shControl virus). The mean RI of the two highest scoring shRNAs was taken for each gene (Table S1 ).
The mean RI of the 25 genes are plotted for all 4 cell lines in Fig 1D. The RI's for the mTORC2 addicted (6.5, 6.8 and shP) and b-abl cells form two distinct non-overlapping classes. Strikingly, shRNA knockdown of none of the genes has an effect on b-abl viability suggesting that they are not involved in bcr-abl driven IL3 independence. We set an arbitrary cut-off and analyzed genes having an RI greater than 20% ( Fig 1E) . Expectedly, as these are mTORC2 addicted cells, mTOR is a hit in all 3 cell lines while the mTORC2 specific component Rictor is also a hit in 2/3 cell lines. Several genes (mRPL27, Cox7A2l, Mff, Dmgdh) have mitochondrial functions, and as previously described, mitochondrial activity is critical for the mTORC2 addicted cells [3] . However, the remaining genes form a seemingly heterogeneous group that may nevertheless share a common role as being downstream effectors of mTORC2 signaling.
A substantial fraction of genes essential in murine mTORC2 addicted cells are also essential in human cancer cell lines To extend these findings from an in vitro transformed murine cell model to human cancer, we selected known PTEN negative cell lines OPM2 (multiple myeloma) and Jurkat (T-cell leukemia) as these cells have high constitutive mTORC2 activity. K562 (chronic myelogenous leukemia) expresses the bcr-abl oncoprotein and was chosen to see whether it would represent an outlier with respect to the other cell lines, similar to the b-abl cell line in the murine cell panel. HL60 (acute myeloid leukemia-M2) is PTEN positive and does not express bcr-abl, it is however insulin dependent for in vitro growth indicating a requirement for mTORC2 signaling [7] . Basal mTOR activity of these cell lines under nutrient-replete conditions (similar conditions as in shRNA screens) was determined by immunoblotting. PTEN negative OPM2 and Jurkat cells as expected had high mTORC2 activity, and slight elevation of mTORC1 signaling (Fig 2A) .
Lentiviral particles for the human counterparts of the 25 essential genes in the mTORC2 addicted murine cells were obtained and used to screen the human cell panel. Unlike the previous screen, there was no possibility of growth factor stimulation corresponding to IL3 to rescue the knockdown of an essential gene. Therefore we needed to measure the infectious titer of each virus in order to discern if an effect on proliferation is biologically relevant due to the knockdown of its target gene, or a technical artefact due to low viral titer. To this end, we infected mouse bcr-abl cells with the human targeting lentiviruses and selected for puromycin resistance. The level of proliferation (as denoted by acquired puromycin resistance) was taken as a measure of the viral titer and was used to normalize infectivity of all the viruses (Table S2 ). shRNA's targeting the essential ribosomal genes RPL32 and RPS17 served as positive controls for cell death. Knockdown of both ribosomal genes were lethal, with RPS17 being more effective and was used to set a baseline for cell death (Table S2 ).
Reduction in cell proliferation after shRNA knockdown of the 25 genes in the human cell panel is shown in Fig 2B. The ratio of inhibition for each lentivirus was calculated from (growth in infected human cells)/(growth in infected b-abl cells) and normalized to the RI of RPS17. The RI for each gene was the mean of the two best lentiviruses. shRNA knockdown of a substantial fraction of the genes inhibited proliferation in all the cell lines with the exception of bcr-abl transformed K562. This parallels the results seen in the mouse panel where only the b-abl line was unaffected by shRNA knockdown of the corresponding murine genes. Accordingly, we set a threshold for effectiveness above the K562 cluster (corresponding to a reduction in proliferation greater than 19%, red dashed line). In the non bcr-abl transformed lines, knockdown reduces cell proliferation in around half of the genes targeted ( Fig 2C) . Rictor knockdown was positive in all 3 cell lines and mTOR in 2 out of 3 lines ( Fig 2D) . Genes encoding for mitochondrial function (MRPL27, Cox7A2l, Mff, Dmgdh) were once again essential.
Thus the list of 25 essential genes obtained from the isogenic mTORC2-addicted murine screen translates very well to a heterogeneous panel of human cancer cell lines. Some of these hits, in particular those from the PTEN negative OPM2 and Jurkat lines, may be due to increased mTORC2 signaling required for oncogenic growth. However, a large number of these hits are also shared in common with HL60 where mTOR signaling is not particularly elevated. None of these hits have a strong impact on growth in K562 suggesting a distinct difference between bcr-abl mediated transformation and other modes of oncogenic transformation with regard to mTOR involvement.
Different requirement for mTOR signaling in bcr-abl and non bcr-abl transformed cells
To investigate dependency on mTOR signaling, cells were titrated with rapamycin and growth measured after 3 days. OPM2 was highly sensitive to rapamycin while K562 was least affected ( Fig 3A) . HL60 and Jurkat cells had reduced proliferation that may be due to the general cytostatic effect of rapamycin on cell proliferation. However, reduced proliferation in OPM2 after rapamycin treatment appears greater than expected from growth arrest alone.
Annexin V staining showed rapamycin induced apoptosis in OPM2 cells while having no effect on K562 ( Fig 3B) . Rapamycin only partially inhibits mTORC1 and is usually ineffective on mTORC2. We therefore used Torin1, an active site inhibitor of both mTORC1 and mTORC2 [8] . Torin1 had a strong negative effect on cell proliferation in HL60 and OPM2 and also decreased growth of Jurkat cells ( Fig 3A) . Inhibition of both TOR complexes however, had little effect on proliferation in K562.
To further dissect the role of mTOR signaling, we performed shRNA knockdown of Rictor and Raptor on cell lines with the greatest divergence in response to mTOR inhibition, namely OPM2 and K562. shRNA knockdown of Raptor (mTORC1) or Rictor (mTORC2) was deleterious to OPM2 while having little effect on K562 (Fig 3C, 3D) . Thus both mTORC1 and mTORC2 are essential for OPM2 growth and viability. In contrast mTOR signaling does not appear to be critical in K562, at least over the time-scale of the assay.
PHD3 is essential for growth and survival in mTOR dependent OPM2
We wished to identify potential cancer therapeutic targets from the list of hits in Table S2 . Of the essential genes in non bcr-abl transformed lines, only mTOR, Rictor, ATP1b3 and PHD3 can be pharmacologically inhibited. Rictor and mTOR signaling are already recognised as bona fide drug targets in oncology while inhibitors of ATP1b3 are non-specific and broadly target many Na + /K + ATPase transporters. We focused on PHD3 (Prolyl hydroxylase 3, EGLN3) which is druggable and has been implicated in cancer [9] .
A growth assay for cells treated with the general prolyl hydroxylase inhibitor DMOG ( Fig 4A) showed that OPM2 was the most sensitive and K562 the least sensitive cell line. Thus response to DMOG within the cell panel mirrors sensitivity to the mTOR inhibitors rapamycin and Torin1 ( Fig 3A) .
OPM2 acutely treated with DMOG showed reduced phosphorylation of S6K but not 4EBP ( Fig 4B) . DMOG appears to selectively inhibit phosphorylation of mTORC1 substrates in a similar fashion as rapamycin [10] .
DMOG inhibits all three cellular prolyl hydroxylases. To determine if the effect on growth was specific to PHD3 inhibition, OPM2 and K562 were infected with lentiviruses bearing shRNAs targeting PHD3. The degree of PHD3 knockdown correlated with growth suppression in OPM2 (Fig 4C, 4D) .
The great number of dying cells in OPM2 infected with shPHD3-49 reduced the amount of protein extracted for immunoblotting ( Fig 4D, GAPDH loading control). In contrast, PHD3 knockdown had no effect on growth in K562.
Discussion
Upregulation of mTOR signaling is a common event in cancer. mTORC1 promotes anabolic processes such as protein translation, lipid and nucleotide biosynthesis and suppresses catabolic processes like autophagy [11] . Our results show that genes essential for survival in an mTORC2 driven murine cancer model are not required in an isogenic bcr-abl driven cancer model (Fig 2A) . This indicates that different signaling networks are activated downstream of either oncogenic driver (Pten loss vs. bcr-abl expression), and that these networks do not appear to share common effector proteins to execute the various essential functions. The validated hits are potential cancer therapeutic targets. Among druggable targets, we focused on PHD3. While generally regarded as a tumor suppressor, PHD3 overexpression is a marker for poor prognosis in clear-cell renal cell carcinoma (ccRCC) [13] , one of the few cancers to respond to rapamycin treatment [14] and supports translation and glycolysis in ccRCC [15] . Depletion of PHD3 activity by pharmacological inhibition or shRNA knockdown led to growth reduction and decreased mTORC1 signaling in OPM2 (Fig 4B, 4C ). mTORC1 activation was previously shown to be sensitive to PHD inhibition [16] . Thus PHD3 is essential for cell viability in a transformed cell line where mTOR signaling is involved in driving cell growth and proliferation.
Materials and Methods
Cell culture
All cells were grown in Iscove's medium supplemented with 10% FCS, 2mM L-glutamine, 100U/ml penicillin, 100µg/ml streptomycin and 50µM bmercaptoethanol at 37°, 5% CO 2 . Derivation of 15V4, 6.5, 6.8 and shP cells has been previously described [3] . b-abl cells were obtained by expressing a bcr-abl construct in 15V4 and selecting for IL3 independence [6] . Murine mast cell medium was supplemented with mouse IL3 from conditioned medium as previously described [3] . Supplementary Data Table S1 Ratio of inhibition for the 25 top-scoring genes in 3 mTORC2-addicted lines (6.5, 6.8, shP), and in b-abl cells. RI values for each gene using the mean of two best scoring oligos for growth -IL3 /growth +IL3 were calculated as described [3] . An RI value >5 corresponds to inhibition of proliferation by >80%.
Cell proliferation assays
Table S2
Ratio of inhibition for the human homologs of the 25 genes from Table S1 tested on a panel of human cancer cell lines. Essential ribosomal genes RPL32 and RPS17 were included as positive controls for cell death. RI for each shRNA was normalized to RPS17. 
